In conclusion, the four identified studies suggest that the use of cannabinoids as co-analgesia in patients with non-neuropathic pain is effective. The patient populations included in the studies varied and included patients with cancer pain, non-cancer pain, rheumatoid arthritis, and acute postherpetic neuralgia. The studies also varied with type of cannabinoid used, the agents used for co-analgesia, and the outcome measurements. The information is limited, and thereforeuncertainty exists with regards to efficacy and adverse events, ideal patient population, dosage, and formulation which may be a consideration for decision-making. Research into a better understanding of patient populations which may benefit the most from an adjuvant cannabinoid and the required dosage combination for co-analgesics considering their adverse-event profile may be needed to inform decision-making.